Polymorphisms of norepinephrine transporter and adrenergic receptor α1D are associated with the response to β-blockers in dilated cardiomyopathy

Pharmacogenomics Journal

Volumn 8, Issue 1, 2008, Pages 78-84

  Nonen, S ^a   Okamoto, H ^b   Fujio, Y ^a   Takemoto, Y ^c   Yoshiyama, M ^c   Hamaguchi, T ^d   Matsui, Y ^b   Yoshikawa, J ^c   Kitabatake, A ^b   Azuma, J ^a  

^a OSAKA UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALPHA 1D ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL; NORADRENALIN TRANSPORTER;

ADRENERGIC SYSTEM; ADULT; AGED; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG DOSE INCREASE; DRUG RESPONSE; FEMALE; GENOTYPE; HEART LEFT VENTRICLE CONTRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM;

ADRENERGIC BETA-ANTAGONISTS; AGED; CARDIOMYOPATHY, DILATED; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, ALPHA-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 38449104944     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500450     Document Type: Article

References (22)

1. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-1355.
2. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprololl CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
3. van Campen LC, Visser FC, Visser CA. Ejection fraction improvement by beta-blocker treatment in patients with heart failure: An analysis of studies published in the literature. J Cardiovasc Pharmocol 1998; 32(Suppl 1): S31-S35.
4. Follath F, Cleland JG, Klein W, Murphy R. Etiology and response to drug treatment in heart failure. J Am Coll Cordiol 1998; 32: 1167-1172.
5. Suwa M, Otake Y, Moriguchi A, Ito T, Hirota Y, Kawamura K et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. Am Heart J 1997, 133: 353-358.
6. 123I]iodobenzylguanidine myocardial scintigraphy for predicting cardiac events in patients with dilated cardiomyopathy who receive long-term beta blocker treatment. Nucl Med Commun 2005; 26: 97-102.
7. Eisenhofer G. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther 2001; 91: 35-62.
8. Tanoue A, Koba M, Miyawaki S, Koshimizu TA, Hosoda C, Oshikawa S et al. Role of the alpha 1D-adrenergic receptor in the development of salt-induced hypertension. Hypertension 2002; 40: 101-106.
9. Chalothorn D, McCune DF, Edelmann SE, Tobita K, Keller BB, Lasley RD et al. Differential cardiovascular regulatory activities of the alpha 1B- and alpha 1D-adrenoceptor subtypes. J Pharmacol Exp Ther 2003; 305: 1045-1053.
10. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprololl European Trial (COMET): Randomised controlled trial. Lancet 2003; 362: 7-13.
11. Hjalmarson A, Waagstein F. COMET: A proposed mechanism of action to explain the results and concerns about dose. Lancet 2003; 362 1077; author reply 1077-1078.
12. Terra SG, Hamilton KK, Pauly DF, Lee CR, Patterson JH, Adams KF et al Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genom 2005; 15: 227-234.
13. Mialet Perez J, Ratlaz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 2003; 9: 1300-1305.
14. Kaye DM, Smirk B, Williams C, Jennings G, Esler M, Holst D. Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics 2003; 13: 379-382.
15. Hod M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004; 147: 324-330.
16. Giessmann T, Modess; C, Hecker U, Zschiesche M, Dazert P, Kunert-Keil C et al. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin Pharmacol Ther 2004; 75: 213-222.
17. Huang J, Chuang SK, Cheng CL, Lai ML. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes. Clin Pharmacol Ther 1999; 65: 402-407.
18. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF. Oxidation phenotype - a major determinant of metoprolol metabolism and response. N Engl J Med 1982; 307: 1558-1560.
19. Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 2000; 275: 23059-23064.
20. Heinonen P, Koulu M, Pesonen U, Karvonen MK, Rissanen A, Laakso M et al. Identification of a three-amino acid deletion in the alpha2B-adrenergic receptor that is associated with reduced basal metabolic rate in obese subjects. J Clin Endocrinol Metab 1999; 84: 2429-2433.
21. Dewar JC, Wheatley AP, Venn A, Morrison JF, Britton J, Hall IP. Beta2-adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population. Clin Exp Allergy 1998; 28: 442-448.
22. Nishiyama T, Ikeda M, Iwata N, Suzuki T, Kitajima T, Yamanouchi Y et al. Haplotype association between GABAA receptor gamma2 subunit gene (GABRG2) and methamphetamine use disorder. Pharmacogenomics 12005; 5: 89-95.